本次保荐代表人变更后，负责公司 2021 年非公开发行股票项目持续督导工 作的保荐代表人为程欣先生和张伟鹏先生。 本次变更不影响中信证券对公司的持续督导工作，公司董事会对王荣鑫先生 在担任公司保荐代表人期间所做的工作表示衷心感谢。 证券代码：603309 证券简称：维力医疗 公告编号：2026-010 广州维力医疗器械股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 中信证券股份有限公司（以下简称"中信证券"）作为广州维力医疗器械股 份有限公司（以下简称"公司"）2021 年非公开发行 A 股股票（以下简称"本次 非公开发行"）项目的保荐机构，持续督导期自 2022 年 1 月 11 日至 2023 年 12 月 31 日。至持续督导期届满，公司本次非公开发行项目的募集资金尚未使用完 毕，中信证券的持续督导义务延至公司募集资金全部使用完毕为止。 中信证券原委派程欣先生和王荣鑫先生担任公司保荐代表人。近日，公司收 到中信证券出具的《关于更换保荐代表人的函》，中信证券将委派张伟鹏 ...

Core Viewpoint - The blood dialysis machine market in China is experiencing rapid growth, with the market size expected to reach 4.131 billion yuan by 2025, reflecting a year-on-year increase of 6.4% [1][6]. Industry Overview - Blood dialysis machines, also known as artificial kidneys, are essential medical devices for treating renal failure and uremia, consisting of a blood monitoring alarm system and a dialysis liquid supply system [3][4]. - The increasing elderly population and rising prevalence of chronic kidney diseases are driving the demand for blood dialysis machines [5][6]. Market Size and Growth - The market size for blood dialysis machines in China is projected to grow significantly, driven by an aging population and an increasing number of patients requiring dialysis treatment [1][6]. - The number of patients undergoing dialysis in China is expected to rise from 385,100 in 2015 to 1,027,300 by 2024, with male patients making up a significant portion of this demographic [5][6]. Competitive Landscape - The Chinese blood dialysis machine industry is primarily dominated by foreign companies such as Fresenius Medical, B. Braun, Baxter, and Nipro, indicating substantial room for domestic companies to capture market share [7][8]. - Domestic companies are enhancing their R&D capabilities, leading to improvements in technology and product quality, which positions them to compete more effectively against international brands [7][8]. Industry Development Trends - The process of domestic substitution for blood dialysis machines is accelerating, with local companies focusing on core technology and key component development to reduce reliance on foreign brands [10][11]. - Future technological advancements in blood dialysis machines will focus on smart and precise upgrades, integrating IoT and AI for improved monitoring and safety [11][12]. - The application scenarios for blood dialysis machines are expanding beyond traditional hospitals to include community healthcare settings and home dialysis solutions, driven by the increasing demand for accessible and convenient treatment options [12].

Core Viewpoint - The announcement details the share pledge situation of the company's controlling shareholder, Gao Bo Investment (Hong Kong) Co., Ltd., including the number of shares pledged and the extension of pledge periods. Group 1: Shareholding and Pledge Details - As of February 24, 2026, Gao Bo Investment holds 92,019,200 shares, accounting for 31.53% of the company's total share capital, with a total of 26 million shares pledged, representing 28.25% of its holdings and 8.91% of the total share capital [1] - The initial pledge of 20 million shares was made on February 26, 2019, with a pledge period ending on February 25, 2021. This was later adjusted to 26 million shares due to a capital increase on May 25, 2020 [2] - The pledge of 26 million shares was extended multiple times, with the latest extension on February 24, 2023, pushing the pledge period to February 25, 2024 [3] Group 2: Recent Developments - On February 24, 2025, the remaining 10 million shares were again pledged, extending the pledge period to February 25, 2026 [4] - Gao Bo Investment has assured that the pledge does not involve guarantees for major asset restructuring or performance compensation [4] - The company emphasizes that the share pledge will not lead to a change in actual control and that Gao Bo Investment has sufficient financial capability to manage risks, with no current risk of forced liquidation [5]

Group 1 - The core point of the article is that Weili Medical announced that as of February 24, 2026, its controlling shareholder, Gao Bo Investment (Hong Kong) Co., Ltd., holds a total of 92.0192 million shares, accounting for 31.53% of the company's total share capital [1] - The company disclosed that a total of 26 million shares have been pledged, which represents 28.25% of the shares held by the controlling shareholder and 8.91% of the company's total share capital [1]

证券代码：603309 证券简称：维力医疗 公告编号：2026-009 广州维力医疗器械股份有限公司 关于控股股东股份延期质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至 2026 年 2 月 24 日，公司控股股东高博投资（香港）有限公司合计 持有公司股份 9,201.92 万股，占公司总股本的 31.53%，累计质押公司股份 2,600 万股，占其所持公司股份的 28.25%，占公司总股本的 8.91%。 广州维力医疗器械股份有限公司（以下简称"公司"）于 2026 年 2 月 24 日接到公司控股股东高博投资（香港）有限公司（以下简称"高博投资"）函告， 获悉其将持有的本公司部分股份进行了延期质押，具体情况如下: 2019 年 2 月 26 日，高博投资将持有的公司 2,000 万股无限售流通股质押给 袁振，质押期限自 2019 年 2 月 26 日起至 2021 年 2 月 25 日。详见公司 2019 年 2 月 28 日披露于《中国证券报》《上海证券报》《证券时报》及上海证券交易 所 ...

Core Viewpoint - Vili Medical (stock code: 603309) is set to experience significant developments in 2026, focusing on capacity expansion, corporate governance, and favorable policies [1] Group 1: Company Project Advancement - The Indonesian factory is scheduled to begin small-scale trial production in March 2026 and officially start production in April 2026, with an initial capacity of 40 million units for nursing products, all supplied to major U.S. clients [2] - The second phase of the factory will involve anesthetic products and urinary catheter products, with a planned capacity of 12 million units in 2026, expected to have a limited impact on gross margin due to pricing negotiations based on costs [2] Group 2: Related Transactions - On January 9, 2026, the company held a board meeting to approve the expected annual related party transactions, with a total amount not exceeding 75 million yuan, which may affect future cash flow and business cooperation [3] Group 3: Subsidiary Development - The wholly-owned subsidiary, Langhe Medical, was re-certified as a high-tech enterprise in 2025, which is expected to enjoy tax benefits [4] - Additionally, the subsidiary Hainan Vili Medical's single-use hydrophilic coated visible nasogastric tube has been included in the fourth batch of innovative drug and medical device products in Hainan Province, benefiting from local policy support to enhance market competitiveness [4] Group 4: Company Status - The pledge situation of the controlling shareholder has improved, with 20 million shares being unpledged by Gaobo Investment on December 30, 2025, reducing the pledge rate to 28.25% as of December 31, 2025, potentially enhancing corporate governance stability [5] - The company released a profit forecast on January 7, 2026, indicating a projected net profit decline of 57%-66% year-on-year, primarily due to the decline in subsidiary operating performance and goodwill impairment, necessitating attention to the upcoming formal audit report [5]

Group 1 - The core viewpoint of the article highlights that Weili Medical (603309) has seen a stock price increase of 4.18%, closing at 14.94 yuan as of February 6, 2026, compared to 14.34 yuan the previous week [1] - The company achieved a total market capitalization of 4.361 billion yuan, ranking 88th out of 129 in the medical device sector and 3870th out of 5186 in the A-share market [1] - The highest intraday price recorded for Weili Medical during the week was 14.99 yuan, while the lowest was 13.85 yuan [1] Group 2 - Weili Medical announced that multiple products have received EU MDR certification, allowing them to be sold in the European market [1] - The certified products include a range of medical devices such as urinary catheter care kits, drainage bags, puncture guides, and various types of catheters and tubes [1] - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028, confirming compliance with the latest EU medical device regulations [1]

Group 1 - The core point of the article is that Weili Medical has received EU MDR certification for multiple products, allowing them to be legally sold in the EU market [1][3]. - On February 5, 2026, Weili Medical's stock closed at 14.57 yuan, with an increase of 1.25% and a trading volume of 52,200 shares, amounting to a total transaction value of 75.83 million yuan [1]. - The net capital flow on February 5 shows a net outflow of 324,100 yuan from main funds, while retail funds experienced a net outflow of 46,400 yuan [1][3]. Group 2 - The products that received EU MDR certification include urinary catheter care kits, drainage bags, puncture guides, nebulizers, and various other medical devices [1]. - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028 [1].

Group 1 - The company has received notification from the EU regulatory body regarding the addition of multiple products to its Medical Device Regulation (MDR) certification [1] - The MDR certification indicates that the products comply with the latest EU medical device regulations, allowing for legal sales in relevant overseas markets [1] - The certification is expected to enhance the promotion and sales of the company's products in the corresponding markets [1] Group 2 - The actual sales performance of the newly certified products in overseas markets will depend on future marketing efforts, and the specific impact on the company's future operating performance remains unpredictable [1]

证券代码：603309 证券简称：维力医疗 公告编号：2026-008 广州维力医疗器械股份有限公司 关于公司产品获得欧盟 MDR 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到欧盟公告机构 通知，公司欧盟医疗器械法规（Medical Device REGULATION (EU) 2017/745，简称 "MDR"）认证证书中新增了多个产品的欧盟 MDR 认证，现将有关情况公告如下： | | | 导尿包 | | | | | | --- | --- | --- | --- | --- | --- | --- | | | | Foley Catheter | Tray | | | | | | | 亲水乳胶导尿管 | | | | | | | | Hydrophilic | Latex | | | | | | | Foley Catheter | | | | | | | | | 亲水硅胶导尿管 | | | | | Ⅱb 类的 | G10 038814 | H ...